Eli Lilly’s two weight loss drugs have become blockbusters, bringing in more than $1 billion in annual revenue. Demand is growing in this market, but so is competition. These players ...

Indian-origin Pulitzer Prize-winning author Jhumpa Lahiri, has declined the prestigious 2024 Isamu Noguchi Award in protest of the Noguchi Museum’s recently implemented dress code policy. Lahiri’s ...

Donanemab, manufactured by Eli Lilly (LLY), is the latest in a new class of anti-amyloid drugs that deliver antibodies to target beta-amyloid, a protein linked to Alzheimer's disease. Initially ...

The best large format printers allow us to take advantage of the resolution of today's best professional digital cameras to print images up to billboard size, something that was once only possible for ...

The most recent trading session ended with Eli Lilly (LLY) standing at $909.32, reflecting a -1.65% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 0.4%.

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

Sept 24 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing patients with another treatment ...

New public and private entrants are emerging to challenge the leading positions of Novo Nordisk NVO and Eli Lilly LLY in a potential $200 billion total GLP-1 market, which we expect will see 68% ...

A onetime business editor at the Detroit Free Press who was part of a team that won a Pulitzer Prize for coverage of the city's 1967 riot and was inducted into the Michigan Journalism Hall of Fame ...

Eli Lilly's long-term growth prospects have been secured by the improved supply in H2'24 and the incoming capacity additions from H1'25 onwards. This is on top of the introduction of its D2C ...

Eli Lilly has become a household name thanks to breakthrough diabetes and obesity care medicines. The stock has trounced the broader market over the past year, and shares have become a bit pricey.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,150.00. Alec Stranahan ...